In the HIV drug market, Gilead leads the way. Its products Truvada have sales of $3.1 billion. Stribild ($205 million), Complera ($800 million), Viread ($958 million), and Antripla ($3.6 billion). Note that 2 of these drugs are joint ventures. Compiler is a joint venture with Johnson & Johnson. Johnson & Johnson’s other HIV products are Prezista ($1.7 billion) and Intelence ($0.3 billion). The other Gilead joint venture is Antripla where proceeds are shared with Bristol-Myers. The other Bristol-Myers HIV drugs are Sustiva ($2.4 billion) and Reyatac ($2.3 billion) Note: for joint ventures assume revenue is divided 50-50. Solve for the HH Index in the HIV drug industry. Show your solution.